Tag Archives: Adverse Event Reporting System

SGLT2 inhibitors: Drug Safety Communication – FDA Warns Medicines May Result in a Serious Condition of Too Much Acid in the Blood

  ISSUE: FDA is warning that the type 2 diabetes medicines canagliflozin, dapagliflozin, and empagliflozin may lead to ketoacidosis, a serious condition where the body produces high levels of blood acids called ketones that may require hospitalization. FDA is continuing … Continue reading

Posted in Medicamentos, Prevencion cuaternaria, tratamiento | Tagged , , , , , , , , , | Leave a comment